Associations between immunogenicity, cellular kinetics, and response rate. (A) Anti-mCAR19 antibodies at enrollment vs tisagenlecleucel cellular kinetics (C_max). (B) Maximum fold change from baseline for anti-mCAR19 antibodies by 3-month response. (C) Cellular immunogenicity vs 3-month response. *Patients who had ≥1 sample with evaluable cellular kinetics data were included. mCAR19, murine anti-CD19 chimeric antigen receptor; MFI, mean fluorescence intensity; SD, stable disease; Unk, unknown.